News | March 13, 2014

Boston Scientific Rebel Stent System Receives CE Marking

Boston Scientific Rebel Platinum Chromium Coronary Stent System Bare Metal

March 13, 2014 — Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).

The Rebel offers physicians the same stent platform as the Promus Premier drug-eluting stent (DES), but without the everolimus drug. Bare metal stents continue to play an important role in the treatment of coronary artery disease and represent a significant portion of the global stent market.

The Rebel features visibility, low recoil, radial strength and fracture resistance, while improving axial strength and deliverability. Its enhanced low-profile delivery system also features a shorter, more visible tip, a dual-layer balloon and a bi-segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions.

The Rebel Stent System is offered in a matrix of 48 sizes, ranging in diameter from 2.25 to 4.5 mm and lengths of 8 to 32 mm on a monorail platform. 

Data from the OMEGA clinical trial evaluating the Platinum Chromium Bare Metal Stent System were presented in February by John C. Wang, M.D., Medstar Union Memorial Hospital, Baltimore, Md. at the Cardiovascular Research Technologies conference, Washington, D.C. OMEGA is a single arm, multi-center trial in the United States and Europe. OMEGA trial data are expected to support a U.S. Food and Drug Administration (FDA) regulatory submission.

In the United States, the Rebel Stent System is an investigational device and not available for sale. 

For more information: www.bostonscientific.com


Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now